The Technical Analyst
Geron Corp [GERN]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Geron Corp Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
-5.76% $3.52
America/New_York / 23 apr 2024 @ 15:50
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 2 067.03 mill |
| EPS: | -0.320 |
| P/E: | -10.98 |
| Earnings Date: | May 09, 2024 |
| SharesOutstanding: | 588.06 mill |
| Avg Daily Volume: | 12.77 mill |
| RATING 2024-04-23 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Sell | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Buy | |
| P/E: | Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -10.98 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -1.87x |
| Company: PE -10.98 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$-0.0317 (-100.90%) $-3.55 |
| Date: 2024-04-23 |
| Expected Trading Range (DAY) |
|---|
|
$ 3.27 - 3.76 ( +/- 6.97%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-02-14 | Feller Faye | Buy | 750 000 | Employee Stock Option (Right to Buy) |
| 2024-02-14 | Kapur Anil | Buy | 750 000 | Employee Stock Option (Right to Buy) |
| 2024-02-14 | Samuels Scott Alan | Buy | 850 000 | Employee Stock Option (Right to Buy) |
| 2024-02-14 | Robertson Michelle | Buy | 850 000 | Employee Stock Option (Right to Buy) |
| 2024-02-14 | Grethlein Andrew J | Buy | 1 200 000 | Employee Stock Option (Right to Buy) |
| INSIDER POWER |
|---|
| 80.20 |
| Last 95 transactions |
| Buy: 25 935 774 | Sell: 3 922 187 |
Forecast:
16:00 - $3.52
Live Trading Signals (every 1 min)
Forecast
1: 15:59 - $3.52
Forecast 2: 16:00 - $3.52
Forecast 3: 16:00 - $3.52
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $3.52 (-5.76% ) |
| Volume | 7.09 mill |
| Avg. Vol. | 12.77 mill |
| % of Avg. Vol | 55.54 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For GERN
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $1.900 | N/A | Active |
|---|
GERN
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
Latest Press Releases
2024-04-18 16:30:00 - Press Release
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Foster city, calif.--(business wire)--geron corporation (nasdaq: gern), a late-stage clinical biopharmaceutical company, today reported that it has granted non-statutory stock options to purchase an aggregate of 243,000 shares of geron common stock as inducements to newly hired employees in connection with commencement of employment with the company. the stock options were granted on april 17, 2024, at an exercise price of $3.68 per share, which is equal to the closing price of geron common sto.
2024-04-03 16:30:00 - Press Release
Geron To Participate At Upcoming Investor Conferences In April
Foster city, calif.--(business wire)--geron corporation (nasdaq: gern), a late-stage clinical biopharmaceutical company, today announced that john a. scarlett, m.d., geron's chairman and chief executive officer, is scheduled to present at the following virtual investor conferences: 23rd annual needham virtual healthcare conference wednesday, april 10th at 10:15 a.m. et (fireside chat) stifel's 2024 virtual targeted oncology days wednesday, april 17th at 11:30 a.m. et (corporate presentation) a.
2024-03-19 09:07:00 - Press Release
Geron Corporation Announces Pricing Of $150 Million Underwritten Offering Of Common Stock And Pre-funded Warrants
Foster city, calif.--(business wire)--geron corporation (nasdaq: gern), a late-stage clinical biopharmaceutical company, today announced the pricing of an underwritten offering consisting of 41,999,998 shares of its common stock at a price of $3.00 per share and pre-funded warrants to purchase 8,002,668 shares of its common stock. the pre-funded warrants are being sold at a price of $2.999 per pre-funded warrant. all of the securities in the offering are to be sold by geron. the offering includ.
2024-03-14 15:54:00 - Press Release
Geron Announces Fda Oncologic Drugs Advisory Committee Votes In Favor Of The Clinical Benefit/risk Profile Of Imetelstat For The Treatment Of Transfusion-dependent Anemia In Patients With Lower-risk Mds
Foster city, calif.--(business wire)--geron corporation (nasdaq: gern), a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies, today announced that the u.s. food and drug administration (fda) oncologic drugs advisory committee (odac) voted 12 to 2 in favor of the clinical benefit/risk profile of imetelstat for the treatment of transfusion-dependent (td) anemia in adult patients with low-to-in.
2024-02-28 07:05:00 - Press Release
Geron Corporation Reports Business Highlights And Fourth Quarter And Full Year 2023 Financial Results
Foster city, calif.--(business wire)--geron corporation (nasdaq: gern), a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies, today reported business highlights and financial results for the fourth quarter and full year 2023. “geron's progress and execution throughout 2023 has paved the way for a potentially transformational 2024, as we plan for the transition to becoming a commercial compan.
Latest News
2024-04-03 16:30:00 - Business Wire
Geron to Participate at Upcoming Investor Conferences in April
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Geron's Chairman and Chief Executive Officer, is scheduled to present at the following virtual investor conferences: 23rd Annual Needham Virtual Healthcare Conference Wednesday, April 10th at 10:15 a.m. ET (Fireside Chat) Stifel's 2024 Virtual Targeted Oncology Days Wednesday, April 17th at 11:30 a.m. ET (Corporate Presentation) A.
2024-03-20 06:10:09 - MarketBeat
Geron Stock Doubles After Imetelstat Receives FDA Panel Approval
Geron Inc. NASDAQ: GERN is a clinical-stage biotech in the medical sector focused on developing cell therapies to treat certain types of blood cancers and myeloid hematologic malignancies. Their lead drug is imetelstat, which blocks a protein called telomerase to treat specific blood cancers like myelofibrosis and myelodysplastic syndromes.
2024-03-18 05:21:00 - PennyStocks
Choosing the Right Penny Stocks, 3 Hot Tips
Navigating the realm of penny stocks can unlock pathways to significant financial growth, presenting a landscape ripe with opportunities for those astute enough to capitalize on them. Central to achieving success in this area is the diligent identification of sectors poised for exponential growth.
2024-03-17 08:31:29 - Invezz
Can Geron Corporation maintain momentum following FDA's backing?
Friday saw an unprecedented surge in the stock of Geron Corporation (NASDAQ:GERN), with shares ending the day up a staggering 92%. This surge, marking a historic milestone for the company, was ignited by a momentous announcement earlier in the day.
2024-03-15 11:50:00 - Market Watch
Geron's stock soars 95% after FDA advisory panel votes in favor of blood-disorder drug
Geron Corp.'s stock rose 95% Friday, after an advisory panel to the Food and Drug Administration voted 12-to-2 in favor of the company's blood-disorder drug imetelstat and said its benefits outweigh the risks.
2024-03-15 10:47:41 - InvestorPlace
Why Is Geron (GERN) Stock Up 94% Today?
Geron (NASDAQ: GERN ) stock is rocketing higher on Friday following news that advisors to the Food and Drug Administration (FDA) are backing its blood disorder drug, imetelstat. According to a press release from late-stage clinical biopharmaceutical company, the Oncologic Drugs Advisory Committee (ODAC) voted 12 to two in favor of imetelstat.
2024-03-15 10:01:46 - Zacks Investment Research
Geron (GERN) Gets ODAC Votes for Blood Disorder Drug, Shares Up
Geron's (GERN) pipeline candidate, imetelstat, gets FDA Committee backing for the treatment of transfusion-dependent (TD) anemia in adult patients with low-to-intermediate-1 risk myelodysplastic syndromes.
2024-03-14 15:28:28 - Reuters
Geron's blood disorder drug gets FDA advisers' backing
Advisers to the U.S. Food and Drug Administration on Thursday voted in favor of Geron's blood disorder drug, stating that, based on late-stage trial data, the benefits outweigh treatment associated risks in patients.
2024-03-12 09:44:41 - Reuters
US FDA staff flags concerns about Geron's anemia treatment
The U.S. health regulator's staff on Tuesday flagged concerns that the late-stage trial data on Geron's anemia drug does not show whether the risks of treatment with imetelstat are outweighed by the potential benefit, documents released ahead of a meeting of independent experts showed.
2024-03-05 10:30:29 - Seeking Alpha
Geron Post 2023 Earnings - Gearing Up For Critical Imetelstat AdCom, PDUFA
Geron Corporation's lead candidate, imetelstat, is awaiting FDA approval for the treatment of transfusion-dependent anemia in adult patients with low-to-intermediate-1 risk myelodysplastic syndromes. The company reported a loss from operations of $194 million in 2023, with $378.1 million in cash at the end of the year. Geron stock has risen by 12% since December, but faces potential risks from an upcoming FDA Advisory Committee meeting and competition from Bristol-Myers Squibb's Reblozyl.